ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Liming Zhu

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. Co-author DOI 10.1186/s13062-024-00513-x ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Changjing Huang · 1 shared paper, 2024 · strength 0.26
- Paper SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity i… DOI 10.1186/s13062-024-00513-x ↗
Huifeng Gao · 1 shared paper, 2024 · strength 0.26
- Paper SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity i… DOI 10.1186/s13062-024-00513-x ↗
Yehua Shen · 1 shared paper, 2024 · strength 0.26
- Paper SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity i… DOI 10.1186/s13062-024-00513-x ↗
Gang Chen · 1 shared paper, 2024 · strength 0.26
- Paper SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity i… DOI 10.1186/s13062-024-00513-x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.